Examiner:

Title: Novel Human G Protein Coupled Receptor

and Polynucleotides Encoding the Same

January 05, 2001

(As amended)

Attorney Docket No.: LEX-0115-USA

B.E. Bunner

## AMENDMENT AND RESPONSE TO OFFICE ACTION DATED MARCH 13, 2002

Commissioner for Patents Washington, D.C. 20231

Sir:

Filed:

The Applicants acknowledge the receipt of the Office Action ("the Action") mailed on March 13, 2002 (Paper No. 8), which has been carefully reviewed and studied. The Examiner is respectfully requested to enter the following amendments. Reexamination and reconsideration of the application is requested in view of the following amendments and remarks. In order to facilitate the Examiner's evaluation of the application, Applicants have attempted to address the objections and rejections in Paper No.8 in the same order in which they were originally raised.

Included herewith as Exhibit A is a clean copy version of the pending claims showing the amendments made herein; as Exhibit B is a marked-up of the claims that will be pending upon entry of the present amendment, as Exhibit C is a marked up copy of the amended paragraphs and as Exhibit D is an amino acid comparison between SEQ ID NO: 1 (known in house as hGPR\_29) and Swiss-Prot Accession No.P58137 and the NCBI entry information on Swiss-Prot:P58137.

A Petition for an Extension of Time of one month to and including July 13, 2002, and authorization to deduct the fee as required under 37 C.F.R. § 1.17(a)(3) from Applicants' Deposit Account are included. The response is thus timely filed. Applicants believe no fees in addition to the fee for the extension of time are due in connection with this response. However, the Commissioner is authorized to charge any underpayment or credit any overpayment to Deposit Account No. 50-0892.